Interestingly, in 71% of IDH-mutated post-MPN AMLs, IDH mutations are associated with SRSF2 mutations; conversely, SRSF2 mutations are associated in 55% of cases with IDH mutations [71]. This evidence concerns the gene SRSF2 and myeloproliferative neoplasm.